IMPACT BIOMEDICAL INC (IBO)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$4.10+1.99%
Close 2026-11-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · IBO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of —
IBO — divestiture
Dated 2026-11-03
Regulation FD Disclosure On November 2, 2026, the Company released a press release relating to the effectiveness of its Form F-4 registration statement (the “Registration Statement”) in connection with the proposed merger with Zoar Limited (f/k/a Dr Ashleys Limited). The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of t…
Why it matters: Stockholder approval is required for the merger to close. A failed vote would block this key step.
Watch forIBO stockholders approve the merger at the special meeting.
Also watch forIBO stockholders reject the merger, or the special meeting is delayed without a new date.
Why it matters: SEC effectiveness is a key step before the merger vote. A delay or rejection would put the deal timeline at risk.
Watch forThe SEC makes Zoar’s Form F-4 effective and sends a final proxy to IBO stockholders.
Also watch forThe SEC does not declare the Form F-4 effective, or Zoar files an amendment that delays the vote.
Why it matters: The split was meant to support the merger and listing goals. Closing would complete the main company priority; failure would leave the deal unfinished.
Watch forIBO and Zoar announce that the merger has closed after the reverse split.
Also watch forThe merger agreement ends, or a required closing condition is still unmet after the vote.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$336 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $839 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,276 loss on $10,000 · 72.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.